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Abstract
Angiotensin-converting enzyme 2 (ACE2) cleaves Angiotensin-II to Angiotensin-(1–7), a cardioprotective peptide. Serum
soluble ACE2 (sACE2) activity is raised in chronic heart failure, suggesting a compensatory role in left ventricular
dysfunction. Our aim was to study the relationship between sACE2 activity, infarct size, left ventricular systolic function and
remodeling following ST-elevation myocardial infarction (STEMI). A contrast-enhanced cardiac magnetic resonance study
was performed acutely in 95 patients with first STEMI and repeated at 6 months to measure LV end-diastolic volume index,
ejection fraction and infarct size. Baseline sACE2 activities, measured by fluorescent enzymatic assay 24 to 48 hours and at 7
days from admission, were compared to that obtained in 22 matched controls. Patients showed higher sACE2 at baseline
than controls (104.4 [87.4–134.8] vs 74.9 [62.8–87.5] RFU/ml/hr, p,0.001). At seven days, sACE2 activity significantly
increased from baseline (115.5 [92.9–168.6] RFU/ml/hr, p,0.01). An inverse correlation between sACE2 activity with acute
and follow-up ejection fraction was observed (r = 20.519, p,0.001; r = 20.453, p = 0.001, respectively). Additionally, sACE2
directly correlated with infarct size (r = 0.373, p,0.001). Both, infarct size (b= 20.470 [95%CI:20.691:20.248], p,0.001) and
sACE2 at 7 days (b= 20.025 [95%CI:20.048:20.002], p = 0.030) were independent predictors of follow-up ejection fraction.
Patients with sACE2 in the upper tertile had a 4.4 fold increase in the incidence of adverse left ventricular remodeling (95%
confidence interval: 1.3 to 15.2, p = 0.027). In conclusion, serum sACE2 activity rises in relation to infarct size, left ventricular
systolic dysfunction and is associated with the occurrence of left ventricular remodeling.
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Spanish Ministry of Science and Innovation [FIS-FEDER PI081688 to Marı́a José Soler Romeo]. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jtortiz@clinic.ub.es
Introduction
The activation of the renin-angiotensin-aldosterone system
(RAAS) is a well-known final pathway following ST-elevation-
myocardial infarction (STEMI), leading to adverse left ventricular
(LV) remodeling, heart failure and cardiac death. In addition to
the cardioprotective effects provided by beta-blockers, it is well
established that pharmacological blockade of the RAAS with
Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin-II
receptor blockers or aldosterone antagonists limit LV remodeling
and improve prognosis following STEMI [1,2]. However, despite
optimal medical treatment with these drugs, many STEMI
patients develop adverse LV remodeling or heart failure during
follow-up [3].
Angiotensin-converting enzyme 2 (ACE2) is an analogue of the
ACE that cleaves Angiotensin-II into Angiotensin-(1–7), a peptide
with vasodilatory properties including an increase in coronary
perfusion and attenuation of post-ischemic LV dysfunction that
antagonizes angiotensin-II actions [4]. ACE2 deficiency in mice
increases angiotensin-II, which causes severe LV dilatation and
systolic dysfunction that is reversed by genetic deletion of ACE [5].
On the other hand, administration of recombinant human ACE2
attenuates angiotensin-II and pressure-overload induced adverse
LV remodeling, suggesting that ACE2 is an important negative
regulator of angiotensin-II induced heart disease [6].
Recently, it has become feasible to measure soluble ACE2
(sACE2) activity in human serum, which allows the non-invasive
study of this component of the RAAS. Serum sACE2 activity has
been also shown to correlate with the presence and severity of
heart failure among patients with ischemic and non-ischemic
cardiomyopathy, to reinforce a cardioprotective and compensato-
ry role in humans [7]. Therefore, ACE2 may potentially exert
beneficial biological effects following STEMI as opposed to ACE
[8,9]. We hypothesized that sACE2 activity would be increased in
STEMI patients and would correlate with infarct size and the
extent of LV dysfunction as assessed by contrast enhanced cardiac
magnetic resonance imaging (ce-CMR).
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Methods
Ethics Statement
Both, the Hospital Clinic of Barcelona Research Committee
and the Ethics Committee for Clinical Research approved this
study. All participants and control subjects signed a consent form.
Patient Population and Sample Collection
From January 15th, 2009 to January 31st, 2010, 270 patients
without prior history of cardiac disease were admitted to the
Coronary Care Unit following STEMI. A total of 98 stable
patients were immediately transferred to the referring hospital
following reperfusion and were not assessed for this study. There
were 8 early deaths and other 20 patients with clinical instability
were excluded. In all, 144 patients were screened for their
participation in the study. Further patient selection is detailed in
Figure 1. Ninety-five patients who completed the first ce-CMR
formed the study group. Of them, 88 (93%) returned for the
follow-up ce-CMR. The standard of care in treating STEMI was
applied. Primary percutaneous intervention was the reperfusion
treatment, delivered by experienced on-call interventional cardi-
ologists following unfractionated heparin, aspirin and a loading
dose of clopidogrel. At the physician’s discretion and unless
contraindicated, captopril or enalapril (at least 6.25 mg every 8
hours or 2.5 mg every 12 hours, respectively), and beta-blockers
were initiated early, usually by 24 hours from admission. Serum
troponin I was measured during 48 hours, every 6 hours during
the first 12 hours and every 12 hours thereafter. In addition, serum
B-type natriuretic peptide (BNP) measured 48 hours after
admission, was available in 76 cases. To determine sACE2 activity
at baseline, blood samples (10 ml) were drawn between 24 and 48
hours after symptoms onset (mean 3465 hours), and at 7 days. A
single blood sample was drawn in a control group, formed by 22
subjects without known cardiovascular disease selected from a
general medicine outpatient clinic. All blood samples from patients
and controls were centrifuged and post-processed similarly. The
isolated serum was stored at –80uC until analysis, which was
performed the same day using the same assay.
ACE2 Enzymatic Assay
The ACE2 fluorescent enzymatic assay protocol was performed
as previously described with modifications, using an ACE2
quenched fluorogenic substrate (Mca-Ala-Pro-Lys(Dnp)-OH,
Enzo Life Sciences) [10,11]. Briefly, 20 mL of serum was incubated
with a buffer (100 mM Tris-HCl, 600 mM NaCl, 10 mM ZnCl2,
pH 7.5) in the presence of protease inhibitors, including 100 mM
captopril, 5 mM amastatin, 5 mM bestatin (all from Sigma-
Aldrich), and 10 mM Z-Pro-prolinal (Enzo Life Sciences). Samples
were incubated with 20 mM quenched fluorogenic substrate in
reaction buffer (final reaction volume 100 mL) at 37uC. Specificity
was determined by pre-incubating serum for 30 minutes with or
without 0.6 mM DX600 (Phoenix Pharmaceuticals), a specific
ACE2 inhibitor [12]. Serum sACE2 activity was determined at 18
hours. The plates were read using a fluorescence plate reader
(Tecan Infinite 200, TECAN Instruments) at an excitation
wavelength of 320 nm and an emission wavelength of 400 nm.
Results are expressed as relative fluorescence units (RFU). To
assess the intra and interobserver variability of sACE2 activity, a
set of 44 serum samples was randomly selected. Then, two
volumes of serum (20 mL) were analyzed in parallel for each serum
sample, and all assays were repeated using the same methodology
with one-week interval between them. The intraassay variability
for sACE2 activity was 4.7260.30%, and the interassay variability
was 6.2360.75%.
To explore whether sACE2 release was related to a membrane
shedding effect, we measured serum levels of tumor necrosis
factor-/ converting enzyme ADAM17 using DuoSet ELISA
development kit (R&D Systems, Minneapolis, MN, USA) and
following manufacturer’s instructions [13]. Samples were diluted
1:2 for the assays, which were performed blinded to patient clinical
characteristics.
Cardiac Magnetic Resonance
A standard ce-CMR study was performed in a 1.5 T clinical
scanner (CV Signa, GE, Milwaukee, USA or Symphony,
SIEMENS, Erlangen, Germany) equipped with cardiac-dedicated
software at a mean of 6.363.4 (range: 3 to 10) days of admission
and repeated at 6.461.0 month. LV function was assessed using a
steady-state free-precession cine sequence prescribed in sequential
10-mm short axis slices with no gap from base to apex to achieve
full LV coverage. The myocardium at risk was assessed by edema
imaging using a dark-blood T2W-SE triple inversion recovery
sequence in the same short-axis positions. Delayed-enhanced
images were acquired 10 to 15 min after intravenous administra-
tion of gadodiamide-DTPA (Omniscan, Amersham Health,
Madrid) at a dose of 0.2 mmol/Kg using a standard segmented
inversion-recovery fast gradient-echo pulse sequence. The inver-
sion time was adjusted to null normal myocardium, typically
between 180 and 320 msec. Matrix size was set to 256 and the
mean field of view was 360 mm, resulting in a typical voxel size of
1.4 by 1.4 by 10 mm. All CMR images were cropped and de-
identified for analysis by an independent experienced observer
blinded to all clinical and angiographic data. The endocardial and
epicardial borders on sequential short axis cine images were
manually traced to compute LV end-systolic volume index (ESVi)
and end-diastolic volume index (EDVi) as well as LV ejection
fraction (EF) using ArgusH software (SIEMENS, Erlangen,
Germany). The hyperenhanced regions on T2 W images were
manually delineated in all short axis slices to compute the
Figure 1. Patient selection. Flow-chart detailing patient selection.
ce-CMR: contrast-enhanced Cardiac Magnetic Resonance; FU: follow-up.
doi:10.1371/journal.pone.0061695.g001
ACE2 Activity in STEMI
PLOS ONE | www.plosone.org 2 April 2013 | Volume 8 | Issue 4 | e61695
myocardium at risk as a percentage of the LV wall. In 32 cases
with insufficient image quality or poor signal-to-noise contrast, we
used the angiographic BARI score as a surrogate of area at risk as
previously reported [14].
A self-customized tool based in MATLAB platform (The
MathWorks, Natick, Massachusetts) was used to compute the
infarct size. First, the endocardial and epicardial borders were
manually traced on short-axis contrast-enhanced images. Similar-
ly, an experienced observer roughly outlined the hyperenhanced
myocardium, and those areas were post-processed with an
algorithm to define the infarcted myocardium according to the
half-maximum pixel intensity criteria [15]. Briefly, a histogram of
the pixel intensities is created for the entire region of interest
manually drawn by the observer. Then, the software identifies the
maximum pixel intensity within the region of interest. The final
infarct extent is automatically defined as those pixels with a signal
intensity above 50% of the maximum of the initial region. The
infarcted areas on sequential short-axis slices were summed and
divided by the total LV wall to calculate infarct size as a
percentage of the LV wall. Microvascular obstruction (MO),
defined as any area of late hypo-enhancement surrounded by
hyperenhancement on ce-CMR images, was also included in the
infarct size. A MO extent score was computed by summing all
segments with MO according to the recommended 17-segment
model.
Statistical Analysis
Normality plots and Shapiro-Wilkoxon’s test confirmed the
non-normality distribution of sACE2 activity data. Accordingly,
enzymatic activities were expressed as median [25th–75th percen-
tiles] as well as time-to-reperfusion. Other quantitative data were
Figure 2. sACE2 activity in controls and patients. Panel A: Box-plot showing the differences in the median (horizontal lines), interquartile range
(boxes) and 95% of the observed values (whiskers) for sACE2 activity between controls and STEMI patients. Panel B: Scatter-plot detailing individual
changes in sACE2 activity among patients. *: p,0.001 for comparison between baseline measurements in patients and controls. {: p,0.01 for
comparison between baseline and 7 days measurements by paired analysis. ACE2: Angiotensin Converting Enzyme 2; RFU: relative fluorometric units.
doi:10.1371/journal.pone.0061695.g002
Table 1. Population demographic characteristics.
STEMI
patients Controls p value
Clinical characteristics (n = 95) (n = 22)
Age (years) 58.3 (12.2) 58.9 (10.8) 0.80
Sex (% male) 82 (86.3) 16 (72.7) 0.19
Body surface area (m2) 1.91 (0.17) 1.91 (0.19) 0.85
Hypertension, n (%) 38 (40.0) 10 (45.5) 0.64
Diabetes, n (%) 20 (21.1) 7 (31.8) 0.27
Hypercholesterolemia, n (%) 43 (45.3) 15 (68.2) 0.06
Smokers, n (%) 72 (75.8) 13 (59.1) 0.12
Data expressed as mean (SD) or number (%).
doi:10.1371/journal.pone.0061695.t001
Table 2. Patient characteristics.
Clinical characteristics (n = 95)
Killip class I, n (%) 76 (80.0)
Killip class II, n (%) 17 (17.9)
Killip class III, n (%) 2 (2.1)
Symptoms-reperfusion time (min)* 181 [135–181]
Angiographic data
Anterior infarction, n (%) 39 (41.1)
Initial TIMI 0/1 flow, n (%) 76 (80.0)
Collateral grades 2/3, n (%) 20 (21.0)
Multivessel disease, n (%) 31 (32.6)
Thrombectomy, n (%) 44 (46.3)
Final TIMI 3 flow, n (%) 87 (91.6)
Final TIMI 2 or 3 flow, n (%) 94 (98.9)
Medical treatment
IIB-IIIA GP inhibitors, n (%) 55 (57.9)
b-Blocker at discharge, n (%) 88 (92.6)
ACE inhibitors at discharge, n (%) 86 (90.5)
ACE inhibitors follow-up, n(%) 85 (89.5)
Statins at discharge, n (%) 94(98.9)
*Data expressed in minutes as median [25th–75th percentiles].
ACE: Angiotensin Converting Enzyme.
doi:10.1371/journal.pone.0061695.t002
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expressed as mean and standard deviation. Categorical data were
summarized as frequencies and percentages, and differences
between groups were assessed using the chi-squared test.
Comparisons of sACE2 activity between groups were performed
using the non-parametric Mann-Whitney U test, and differences
over time within subjects were evaluated by paired analysis.
Bivariate associations between ACE2 activity, infarct size and
other quantitative variables were assessed by the Spearman’s
correlation coefficient. One-way analysis of variance was used
among sACE2 intertertile range for the various clinical parame-
ters. A multivariate linear regression model was constructed to
identify independent significant predictors of final EF, including
logarithmic-transformed ACE2 activity and other significant
univariate predictors. In order to assess infarct size variability,
two independent observers measured 40 randomly selected studies
twice. The Lin’s concordance correlation coefficient was 0.96
(95% confidence interval: 0.94–0.98) for intraobserver variability
and 0.92 (95% confidence interval:0.90–0.95). SPSS version 15.0
for Windows was used, and a p value ,0.05 was considered
statistically significant for all tests used.
Results
ACE2 Activity in Controls and Patients
Patients (n = 95) and controls (n = 22) were well matched for sex,
age, and risk factors (Table 1). The clinical status, the angiographic
findings as well as the medical treatment for STEMI patients are
shown in table 2. Patients showed increased sACE2 activity at
baseline as compared to controls (p,0.001). Among STEMI
patients, a significant increase in sACE2 activity from baseline to 7
days was observed (Table 3 and Figure 2). We found no significant
association between sACE2 activity and age, diabetes, hypercho-
lesterolemia, hypertension or tobacco use. At baseline, sACE2
activity was not significantly different among 66 subjects being
treated with ACE inhibitors as compared to subjects who were not
(104.9 [87.4–139.1] vs 102.6 [86.6–119.3] RFU/ml/hr, p = 0.686).
No differences were also found in sACE2 activity at 7 days among
87 subjects being treated with ACE inhibitors as compared to 8
subjects who were not taking ACE inhibitors (115.3 [93.0–159.4]
vs 120.8 [93.1–224.2] RFU/ml/hr, p = 0.471).
We found sACE2 activity at 7 days to be increased in 19
patients in Killip class 2 or 3 during admission as compared to
patients in Killip 1 (181.5 [136.4–224.1] vs 104.5 [86.0–137.6]
RFU/ml/hr, respectively, p,0.001. A correlation was found
between sACE2 activity at 7 days and the myocardium at risk
derived from T2 W imaging, (r = 0.373, p,0.001). The results
were similar when only the angiographic measurements of
myocardium at risk where taken into account for all patients.
Infarct size derived from ce-CMR weakly correlated with sACE2
activity at 7 days (r = 0.354, p,0.001) and 6 months follow-up
(r = 0.328, p,0.01), (Figure 3). sACE2 activity at 7 days was not
significantly different between patients with and without MO on
CMR (121.0 [92.2–174.9] vs 114.6 [91.7–159.5] RFU/ml/hr
respectively, p = 0.556. We found no correlation between sACE2
activity at 7 days and MO score (r = 0.159, p = 0.129).
Serum ADAM17 was not significantly different between
controls and patients at baseline (1001 [477–1646] vs 1067
[822–1536] pg/ml, p = 0.437). ADAM17 was not correlated with
sACE2 activity at baseline (r = 20.103, p = 0.351) or 7 days
(r = 0.041, p = 0.712). We found no association between serum
ADAM17 and infarct size by ce-CMR at 7 days (r = 0.047,
p = 0.666) or 6 months (r = 20.015, p = 0.898).
Predictors of Late Systolic Function
Infarct size by ce-CMR (r = 20.705, p,0.001) or peak
troponins (r = 20.675, p,0.001), MO score (r = 20.493,
p,0.001), the initial BNP (r = 20.404, p,0.001), sACE2 at 7
days (r = 20.350, p,0.01) and the myocardium at risk
Table 3. sACE2 laboratory results.
Group Baseline sACE2 7 days sACE2
Controls 74.9 [62.8–87.5] –
STEMI patients 104.4 [87.4–134.8]* 115.5 [92.9–168.6]**
Data expressed as relative fluorometric units per microliter per hour (RFU/ml/hr).
*p,0.001 for comparison between baseline values in controls and STEMI
patients by Mann-Whitney U test.
**p,0.01 for comparison between baseline and 7 days values in patients by
paired Wilcoxon test.
sACE2: Serum Angiotensin Converting Enzyme 2.
doi:10.1371/journal.pone.0061695.t003
Figure 3. Correlation between sACE2 activity and infarct size. A weak but significant correlation was observed between infarct size and
sACE2 activity at 7 days (panel A) and at 6 months follow-up (panel B). FU: Follow-up. sACE2: Serum Angiotensin Converting Enzyme 2; LV: left
ventricular; RFU: relative fluorometric units.
doi:10.1371/journal.pone.0061695.g003
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(r = 20.304, p,0.01) were univariate predictors of late EF.
Figure 4 shows the correlation between sACE2 activity at 7 days
and acute or follow-up EF. By multivariate linear regression
analysis, ACE2 activity at seven days and infarct size by ce-CMR
were the only two independent predictors of late EF (Table 4).
ACE2 Activity and Remodeling
Although many variables including myocardium at risk, infarct
size, MO extent, ACE2 activity and BNP correlated with LV
ESDi and EDVi at baseline and follow-up, ACE2 activity was the
only predictor of % increase in EDVi (r = 0.291, p,0.01). Fifteen
(16.9%) subjects presented adverse LV remodeling at follow-up,
defined as an increase $20% in the follow-up EDVi as compared
to baseline. They had increased ACE2 activity at 7 days (156.6
[118.2–231.1] vs 111.7 [86.5–142.6] RFU/ml/hr, p = 0.011).
However, infarct size and MO extent were not significantly
different between both groups (18.4612.8% vs 17.2611.0% and
1.762.3 vs 1.261.7 segments respectively, p = ns for both).
Neither BNP nor peak troponins were different in both groups
(see Table S1 for further details). Furthermore, differences in LV
remodeling can be illustrated when subdividing the 88 subjects
with follow-up CMR into tertiles based on the sACE2 activity
found at 7 days. As shown in Table 5, the proportion of patients
with heart failure during admission or adverse LV remodeling
increased according to sACE2 activity tertiles. A significant linear
association was observed between EF and infarct size among
sACE2 activity tertiles. In general, mean EF improved on follow-
up among the three groups. However, different adaptive changes
in ESVi and EDVi were observed according to sACE2 tertiles.
The odds ratio of predicting adverse LV remodeling with sACE2
activity above the third tertile after adjustment for age was 4.4 (1.3
to 15.2, p = 0.027 by Fisher’s Exact Test).
Discussion
There are several novel findings in this study. First, ACE2 is
upregulated in the acute phase of STEMI in humans and can be
determined non-invasively by measuring sACE2 activity. Second,
sACE2 activity was found to correlate with the infarct size. Finally,
in addition to infarct size, ACE2 activity measured acutely is
associated with late LV systolic function and occurrence of adverse
LV remodeling.
A significant activation of the RAAS occurs after myocardial
infarction, leading to a marked increase in Angiotensin-II
generation by ACE, which promotes fibrosis and marked adverse
LV remodeling [16]. However, despite optimal medical treatment
with ACE inhibitors or Angiotensin-II receptor blockers, many
patients develop adverse remodeling and heart failure. It follows
Figure 4. sACE2 activity and LV systolic function. Scatter-plots showing a statistically significant correlation between ACE2 activity at 7 days
and EF during admission (panel A) and at 6 months follow-up (panel B). sACE2: Serum Angiotensin Converting Enzyme 2; EF: ejection fraction; RFU:
relative fluorometric units.
doi:10.1371/journal.pone.0061695.g004
Table 4. Predictors of follow-up EF by multivariate analysis.
r2 model Variable b coefficient
95% CI
of b t p value
r2 = 0.643 Infarct size (%LV) 20.470 20.691:20.248 24.240 ,0.001
sACE2 activity
(7 days)
20.025 20.048:20.002 22.218 0.030
BNP 20.007 20.018:0.05 21.162 0.250
Myocardium
at risk
0.059 20.097:0.216 0.76 0.450
MO extent 20.364 21.548:0.819 20.615 0.541
Troponin peak 20.005 20.018:0.008 20.740 0.462
Sex 24.532 29.316:0.252 21.894 0.063
BNP: B-type natriuretic peptide; MO: microvascular obstruction; sACE2: Soluble Angiotensin Converting Enzyme 2; CI: confidence interval.
doi:10.1371/journal.pone.0061695.t004
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that additional medical treatment seems desirable. In the last
decade, significant attention has been paid to the role of ACE2 in
cardiac disease and hypertension. In the heart, ACE2 is the
primary pathway for the metabolism of Angiotensin-II by cleavage
into Angiotensin-(1–7), a peptide with opposed biological actions
as compared to ACE [17]. The genetic loss of ACE2 in mice
causes increased levels of Angiotensin-II and progressive mild LV
dilatation with concomitant systolic dysfunction that is restored by
ACE deletion, suggesting that this response is mediated by an
increase in Angiotensin-II levels.
The role of ACE2 in acute myocardial infarction has been
addressed in experimental studies. There is evidence that ACE2
protein is increased in the infarct-related and peri-infarct
myocardium [8,18]. Interestingly, treatment with ramipril had
no effect on cardiac ACE2 mRNA expression or ACE2 activity,
which remained elevated. ACE2-deficient mice showed greater
infarct size, contractile dysfunction and more severe LV dilatation
that persisted 8 weeks after myocardial infarction [18]. On the
other hand, overexpression of cardiac ACE2 achieved by lentivirus
transfection prior to myocardial infarction conferred early
ischemic protection, including a significantly decrease in infarct
size assessed by ce-CMR and marked recovery of contractility in
the infarct and the remote non-infarcted myocardium [19].
Taking these studies together, it seems reasonable to summarize
that ACE2 loss post-infarction is detrimental and ACE2 overex-
pression confers cardioprotection against adverse LV remodeling
and contractile dysfunction.
In humans, there is evidence for an upregulation of ACE2 gene
expression and activity in failing hearts with ischemic and non-
ischemic cardiomyopathy, and among diabetic patients with heart
disease, suggesting a regulatory role of the enzyme in advanced
heart failure [9,20]. An increase in Angiotensin-(1–7) forming
activity was found in the heart of subjects with end-stage idiopathic
cardiomyopathy that was abolished with the specific ACE2
inhibitor C16. In addition, the presence of ACE2 protein was
confirmed by Western blot analysis in those hearts [21]. Serum
sACE2 activity is measured as the result of a proteolytic shedding
effect in cell membranes, giving the opportunity to track this
pathway activation non-invasively. Using this methodology, Epel-
man et al. showed increased sACE2 activity among patients with a
clinical diagnostic of heart failure [7]. Moreover, sACE2 activity
correlated with the NYHA class, LV ejection fraction and B-type
natriuretic peptide levels. This relationship was observed among
patients with ischemic and non-ischemic cardiomyopathy at
different stages, again suggesting a compensatory mechanism to
limit LV dysfunction. In line with these studies, sACE2 activity
correlated with the severity of LV dysfunction in other conditions,
such as Chagas’ disease. Remarkably, plasma ACE2 activity was
equally potent as BNP to predict cardiac death and heart
transplantation [22]. In our study, the enzyme activity is related
to infarct size and particularly with the ischemic territory at risk,
which parallels the association between ACE2 loss and stunning/
hibernation described in experimental models. Although ACE2 is
mainly localized in the endothelium, we found no association
between sACE2 and the presence or severity of microvascular
obstruction on ce-CMR, as it would have been expected in cases of
severe endothelial damage. One plausible explanation for this
finding might be the impaired tissue perfusion observed in areas of
severe microvascular obstruction, which limits the enzyme leakage
into the blood stream. ACE2 activity in plasma has been shown to
increase in the first week in a murine model of non-reperfused
myocardial infarction [23]. Our study is the first to describe a
proportional upregulation of sACE2 activity to infarct size and LV
dysfunction in human myocardial infarction. ACE and ACE2
activation following STEMI may influence fibrosis deposition,
finally leading to adverse LV remodeling. In this study, the
upregulation of ACE2 seen during the acute phase was also
correlated with fibrosis on ce-CMR measured at 6 months follow-
Table 5. Clinical characteristics based on tertile plasma sACE2 activity at 7 days.
Variable* sACE2 tertile 1 sACE2 tertile 2 sACE2 tertile 3 P value{
sACE2 (RFU/ml/hr) ,100.7 100.7–140.8 .140.8 –
Age (yrs) 59.8 [55.4–64.2] 56.4 [51.7–61.1] 58.3 [53.8–62.8] 0.560
Killip.1 (%) 3.1 17.9 41.9 0.001
Multivessel dis. (%) 18.8 46.4 36.7 0.068
Diabetes 15.6 17.9 29.0 0.380
Hypertension 43.8 35.7 35.5 0.747
ACE inhibitors (%) 90.6 92.9 87.1 0.755
b-Blockers (%) 84.4 92.9 100.0 0.066
CMR characteristics
Infarct size (%LV) 13.4 [10.0–16.7] 16.9 [13.2–20.6] 23.9 [18.9–28.9] 0.001
Initial EF (%) 53.4 [51.2–55–6] 48.5 [45.8–51.2] 40.7 [36.7–44.7] ,0.001
Follow-up EF (%) 55.9 [53.5–58.3] 53.4 [50.5–56.3] 46.6 [42.3–51.0] ,0.001
% D EDVi 1.6 [24.5–7.8] 4.1 [24.6–12.8] 14.7 [6.2–23.1] 0.043
% D ESVi 23.6 [29.2–1.9] 24.7 [215.1–5.8] 6.9 [24.3–18.3] 0.147
LV remodeling (%) 6.9 10.7 33.3 0.017
MO score 0.8 [0.4–1.3] 1.5 [0.8–2.2] 2.0 [1.1–2.8] 0.057
*Continuous variables expressed as mean [95% confidence interval].
{Analysis of variance across sACE2 quartiles, chi-square test for nominal variables. CMR = cardiac magnetic resonance; EF = ejection fraction; EVDi = end-diastolic volume
index; ESVi = end-systolic volume index; LV = left ventricular; MO = microvascular obstruction.
LV remodeling is defined as an increase in EDVi$20%.
doi:10.1371/journal.pone.0061695.t005
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up. However, more precise methods to depict interstitial diffuse
fibrosis by ce-CMR as a result of RASS system activation were not
applied in our study. ACE2 activity was significantly higher among
patients that developed marked dilatation (DEDVi .20%)
between the baseline and follow-up ce-CMR study. Importantly,
no differences were found in infarct size between patients who
developed or not marked dilatation during the study. Therefore, a
subset of patients with small infarct size and near normal EDVi at
baseline with optimal medical treatment may be at risk for
developing adverse remodeling and could be identified based on
non-invasive determination of sACE2 activity. Regardless of this
marginal clinical utility, the ultimate goal of measuring sACE2
activity depends on the ability to target medically the activation of
ACE2-Angiotensin (1–7) pathway, rather than serving as a non-
invasive tool to predict the occurrence of adverse LV remodeling
following myocardial infarction.
There are several limitations in this study. The sACE2 activity
was higher in patients than controls at baseline. However, enzyme
activity was not repeated in controls at 7 days. Herein, the
possibility of sACE2 increase observed among patients being a
random finding cannot be totally ruled out. Whether the increase
in circulating ACE2 is the cause or the effect of LV remodeling
following STEMI remains uncertain. Cleavage of membrane
ACE2 by up-regulated proteases in advanced heart failure, such as
tumor necrosis factor-/ ADAM17 may deplete local myocardial
ACE2 causing LV remodeling. We found no differences in serum
ADAM17 between patients and controls. In addition, ADAM17
did not correlate with sACE2. However, we did not measure
ADAM17 and ACE2 in the myocardium, and therefore a local
shedding effect causing increased sACE2 cannot be excluded.
Alternatively, release of membrane ACE2 in plasma may
represent a compensatory mechanism to limit heart failure by
means of increasing systemic Angiotensin (1–7) against Angioten-
sin-II actions. Measurements of circulating Angiotensin-II or
Angiotensin 1–7 were not available and therefore, our study do
not provide the mechanism for the supposed protective role of
ACE2 in STEMI, that will need further evaluation. We performed
the initial CMR a mean of 6 days after the index event, when most
of LV remodeling has probably occurred. In addition, we did not
include clinically unstable patients in whom the ce-CMR study
could not be performed. Those are the patients with more adverse
remodeling and larger infarct size. These facts might have limited
the true relationship found between infarct size, LV remodeling
and sACE2 activity. As a result, the correlations found between
sACE2, infarct size, LV EF or remodeling were modest. However,
our purpose was to demonstrate a relationship between ACE2
activation and LV dysfunction to support future therapeutic
developments rather than using the measure as a clinical tool to
predict adverse remodeling.
Conclusions
To our knowledge, this is the first study reporting that sACE2
activity is increased in the acute phase of STEMI in humans and
correlates with the extent of jeopardized myocardium and infarct
size. ACE2 activity measured acutely seems to be an independent
predictor of late LV systolic function and it is also associated with
the occurrence of adverse remodeling. Further pathophysiological
and mechanistic studies are warranted to elucidate whether this
association, that has been shown to be present in several cardiac
conditions causing left ventricular dysfunction, may become a new
target for therapy following STEMI.
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